On May 2, 2025, prominent analyst Brian Skorney from Baird released an update on Biogen (BIIB, Financial), maintaining their "Outperform" rating on the biotech giant. However, Skorney adjusted the price target for BIIB, lowering it from $300.00 to $255.00 USD. This represents a 15% decrease in the projected value of the company's stock.
The modified price target reflects a revised outlook by Baird, yet the maintained "Outperform" rating suggests continued confidence in Biogen’s market performance relative to its peers. Investors considering BIIB should note the potential implications of this adjusted price target, despite the positive rating remaining unchanged.
Biogen (BIIB, Financial) continues to be a focal point in the biotechnology sector, attracting attention from analysts and investors alike. Stay informed with the latest updates on BIIB as market dynamics evolve and analysts provide further insights.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $180.15 with a high estimate of $300.00 and a low estimate of $115.00. The average target implies an upside of 48.97% from the current price of $120.93. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.68, suggesting a upside of 75.04% from the current price of $120.93. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
